Data from previous studies evaluating the efficacy of atezolizumab, a PD-L1 inhibitor, have suggested that high tissue tumor mutational burden may be predictive of efficacy for checkpoint immunotherapy.
Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.
Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the findings at the ASCO 2018 meeting.
Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.
Raymond L. Comenzo, MD, discusses his findings at the ASCO 2018 meeting.
James L. Gulley, MD, PhD, FACP, discusses his findings at ASCO 2018 meeting.
Paul Nghiem, MD, PhD, discusses his findings at the ASCO 2018 meeting.
Kyu Rhee, MD, MPP, discusses the latest updates at the ASCO 2018 meeting.
Previous studies demonstrated that FOLFIRINOX is more effective than gemcitabine as first-line treatment for patients with metastatic pancreatic cancer with good performance status.
